eCite Digital Repository

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

Citation

Bukhari, W and Khalilidehkordi, E and Mason, DF and Barnett, MH and Taylor, BV and Fabis-Pedrini, M and Kermode, AG and Subramanian, S and Waters, P and Broadley, SA and Broadley, SA and Abernethy, D and Bhuta, S and Blum, S and Boggild, M and Boundy, K and Brew, BJ and Brilot, F and Brownlee, WJ and Bundell, CS and Butzkueven, H and Carroll, WM and Chen, C and Clarke, L and Coulthard, A and Dale, RC and Das, C and Dear, K and Fulcher, D and Gillis, D and Hawke, S and Heard, R and Henderson, APD and Heshmat, S and Hodgkinson, S and Jimenez Sanchez, S and Kilpatrick, TJ and King, J and Kneebone, C and Kornberg, AJ and Lechner-Scott, J and Lin, MW and Lynch, C and Macdonell, RAL and Marriott, MP and McCombe, PA and Oa Gorman, C and Parratt, JDE and Pender, MP and Pereira, J and Pollard, JD and Prain, KM and Ramanathan, S and Reddell, SW and Shaw, C and Silvestrini, RA and Slee, M and Spies, J and Stankovich, J and Sutton, I and Vincent, A and Vucic, S and Walsh, M and Willoughby, E and Wong, RC and Woodhall, M and Yiu, EM and The Australian and New Zealand NMO Collaboration, NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand, Journal of Neurology ISSN 0340-5354 (2021) [Refereed Article]

Copyright Statement

Crown 2021

DOI: doi:10.1007/s00415-021-10665-9

Abstract

Background: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences.

Methods: Cases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared.

Results: There were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.522.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.151.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.000.80) per 100,000.

Conclusion: The prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.

Item Details

Item Type:Refereed Article
Keywords:neuromyelitis optica, aquaporin, Maori, Aboriginal and Torres Strait Islander, genetics
Research Division:Biomedical and Clinical Sciences
Research Group:Neurosciences
Research Field:Neurology and neuromuscular diseases
Objective Division:Health
Objective Group:Clinical health
Objective Field:Diagnosis of human diseases and conditions
UTAS Author:Taylor, BV (Professor Bruce Taylor)
UTAS Author:Stankovich, J (Dr Jim Stankovich)
ID Code:146187
Year Published:2021
Deposited By:Menzies Institute for Medical Research
Deposited On:2021-08-24
Last Modified:2021-09-03
Downloads:0

Repository Staff Only: item control page